Research Analysts Offer Predictions for Ovid Therapeutics Inc.'s Q1 2024 Earnings (NASDAQ:OVID)

Ovid Therapeutics Inc. (NASDAQ:OVID – Free Report) – Equities research analysts at B. Riley issued their Q1 2024 earnings per share (EPS) estimates for shares of Ovid Therapeutics in a research note issued to investors on Monday, April 29th. B. Riley analyst K. Patel expects that the company will earn ($0.26) per share for the […]

Related Keywords

China ,United States ,Jeremym Levin , ,Ovid Therapeutics Company Profile ,Ovid Therapeutics Inc ,Securities Exchange Commission ,Sg Americas Securities ,China Universal Asset Management Co ,Jump Financial ,Connor Clark Lunn Investment Management Ltd ,Nasdaq ,Ovid Therapeutics ,Free Report ,Covid Therapeutic ,Get Free Report ,Universal Asset Management ,Connor Clark ,Lunn Investment Management ,Exchange Commission ,Therapeutics Inc ,Ovid Therapeutics Daily ,Nasdaq Ovid ,Covid ,Medical ,Earnings Estimates ,B Riley ,